-

01:07:35 PM

LIVE Real Time BFRA Stock Market News

BFRA - Biofrontera AG

04/12/21 1:57 PM

Nasdaq : BFRA

Biofrontera reports results for the 2020 financial year

Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today reported its consolidated results for the fiscal year ended December 31, 2020. At the same time, the Company

RHEA-AI

neutral

04/08/21 10:30 AM

Nasdaq : BFRA

Biofrontera announces preliminary revenue for Q1 2021

Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the first quarter 2021. The Company's preliminary unaudited revenue

RHEA-AI

neutral

03/31/21 10:12 AM

Nasdaq : BFRA

Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results

Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, will be releasing its financial results for the fiscal year 2020 on Monday, April 12, 2021. Conference calls for

RHEA-AI

neutral

03/31/21 3:40 AM

Nasdaq : BFRA

Biofrontera submits application for FDA approval of new BF-RhodoLED(R) XL lamp

Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the submission for approval of a new, significantly larger red-light source for photodynamic therapy

RHEA-AI

very positive

02/26/21 9:20 AM

Nasdaq : BFRA

Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million

Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) ("Biofrontera" or the "Company"), an international biopharmaceutical company, announces the closing of the capital increase resolved by the annual general meeting on May 28, 2020.

RHEA-AI

neutral

02/24/21 8:30 AM

Nasdaq : BFRA

Biofrontera submits study report of pharmacokinetics study to FDA

Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, announces the submission of an application to the U.S. Food and Drug Administration (FDA) to amend the product

RHEA-AI

neutral

02/23/21 7:54 PM

Nasdaq : BFRA

Biofrontera AG Announces Pricing of US$8.9 Million Firm Commitment Public Offering of American Depositary Shares

Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) ("Biofrontera" or the "Company"), an international biopharmaceutical company, today announced the pricing of a U.S. underwritten

RHEA-AI

neutral

10/14/20 4:30 AM

Nasdaq : BFRA

Biofrontera AG: Receives reasons from the Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court

Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, had announced on September 22, 2020, that in a ruling from September 22, 2020, the German Federal Supreme Court has

RHEA-AI

negative

10/09/20 10:32 AM

Nasdaq : BFRA

Biofrontera reports preliminary unaudited sales revenue for the third quarter of 2020

Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today reports preliminary unaudited revenue for the third quarter of fiscal year 2020. The Biofrontera-Group generated

RHEA-AI

neutral

10/08/20 11:03 AM

Nasdaq : BFRA

Biofrontera AG reports completion of the clinical phase of the pharmacokinetics study

Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, reports the completion of the clinical phase (last subject last visit) of the pharmacokinetics study (PK study) to test

RHEA-AI

neutral